- Home
- ADVM vs VANI Comparison
ADVM vs VANI Comparison
Compare ADVM & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- VANI
- Stock Information
- Founded
- ADVM 2006
- VANI 1998
- Country
- ADVM United States
- VANI United States
- Employees
- ADVM N/A
- VANI N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ADVM Health Care
- VANI Health Care
- Exchange
- ADVM Nasdaq
- VANI Nasdaq
- Market Cap
- ADVM 94.6M
- VANI 81.2M
- IPO Year
- ADVM 2014
- VANI 2014
- Fundamental
- Price
- ADVM $4.32
- VANI $1.51
- Analyst Decision
- ADVM Buy
- VANI Strong Buy
- Analyst Count
- ADVM 5
- VANI 1
- Target Price
- ADVM $16.60
- VANI $4.00
- AVG Volume (30 Days)
- ADVM 1.0M
- VANI 492.5K
- Earning Date
- ADVM 11-07-2025
- VANI 11-13-2025
- Dividend Yield
- ADVM N/A
- VANI N/A
- EPS Growth
- ADVM N/A
- VANI N/A
- EPS
- ADVM N/A
- VANI N/A
- Revenue
- ADVM $1,000,000.00
- VANI N/A
- Revenue This Year
- ADVM $1,449.40
- VANI N/A
- Revenue Next Year
- ADVM N/A
- VANI N/A
- P/E Ratio
- ADVM N/A
- VANI N/A
- Revenue Growth
- ADVM N/A
- VANI N/A
- 52 Week Low
- ADVM $1.78
- VANI $0.91
- 52 Week High
- ADVM $8.18
- VANI $1.92
- Technical
- Relative Strength Index (RSI)
- ADVM 50.91
- VANI 47.56
- Support Level
- ADVM $4.18
- VANI $1.59
- Resistance Level
- ADVM $4.34
- VANI $1.81
- Average True Range (ATR)
- ADVM 0.26
- VANI 0.15
- MACD
- ADVM -0.05
- VANI -0.01
- Stochastic Oscillator
- ADVM 40.96
- VANI 27.19
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.